AFG1L

Across TCGA pan-cancer cohorts, AFG1L mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated AFG1L data layer compared with 24 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher AFG1L mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated AFG1L expression acts as an unfavorable survival marker, although some lineages such as PDAC and CCRCC show a favorable association.

PDAC, CCRCC, and HNSC are the cancer types where AFG1L mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Median	IV	0.785	0.214	.006	25	view →
CCRCC	DFS	Quartile	II,III,IV	1.000	0.361	.036	4	view →
HNSC	DFS	Tertile	All	0.978	0.355	.014	4	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

AFG1L–PDAC (DFS)

Open the PDAC breakdown →